FindTrial
Sign In

A Real-World Study on the Efficacy and Safety of Different Doses of Amoxicillin Combined with Potassium-Competitive Acid Blockers in Helicobacter Pylori Eradication

A Real-World Study on the Efficacy and Safety of Different Doses of Amoxicillin Combined with Potassium-Competitive Acid Blockers in Helicobacter Pylori Eradication

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126677
Enrollment
Unknown
Registered
2026-06-13
Start date
2026-06-30
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Medium-dose group:None
High-dose group:None
Low-dose group:None

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Confirmed positive for Hp infection by 13C/14C-UBT or pathological diagnosis (if using 13C-UBT, the cutoff value must be above 6; if using 14C-UBT, the value must be more than twice the critical value to be included); 2. Treated for Helicobacter pylori in our hospital's specialized Hp clinic using dual therapy with amoxicillin combined with a potassium-competitive acid blocker; 3. Patients who had a follow-up check 4 weeks after the end of treatment to determine if eradication was successful.

Exclusion criteria

Exclusion criteria: Patients who cannot be queried and refuse follow-up.

Design outcomes

Primary

MeasureTime frame
Helicobacter pylori eradication rate;—

Secondary

MeasureTime frame
Incidence of adverse reactions, Treatment compliance;Clinical symptom relief rate;—

Countries

China

Contacts

Public ContactWang Youhua

The First Affiliated Hospital of Nanchang University

youhua_wang@ncu.edu.cn+86 791 88694553

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026